Tenaya Therapeutics Inc
NASDAQ:TNYA
Intrinsic Value
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of TNYA.
Fundamental Analysis
Balance Sheet Decomposition
Tenaya Therapeutics Inc
| Current Assets | 111.6m |
| Cash & Short-Term Investments | 104.6m |
| Other Current Assets | 6.9m |
| Non-Current Assets | 58.9m |
| PP&E | 53.3m |
| Other Non-Current Assets | 5.7m |
| Current Liabilities | 22.7m |
| Accounts Payable | 5.6m |
| Accrued Liabilities | 16.6m |
| Other Current Liabilities | 485k |
| Non-Current Liabilities | 8.4m |
| Other Non-Current Liabilities | 8.4m |
Earnings Waterfall
Tenaya Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-131.2m
USD
|
|
Operating Income
|
-131.2m
USD
|
|
Other Expenses
|
7.1m
USD
|
|
Net Income
|
-124.1m
USD
|
Free Cash Flow Analysis
Tenaya Therapeutics Inc
What is Free Cash Flow?
TNYA Profitability Score
Profitability Due Diligence
Tenaya Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Tenaya Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
TNYA Solvency Score
Solvency Due Diligence
Tenaya Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Tenaya Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TNYA Price Targets Summary
Tenaya Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for TNYA is 19.82 USD with a low forecast of 7.07 USD and a high forecast of 42 USD.
Ownership
TNYA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
TNYA Price
Tenaya Therapeutics Inc
| Average Annual Return | -30.46% |
| Standard Deviation of Annual Returns | 83.62% |
| Max Drawdown | -94% |
| Market Capitalization | 342.3m USD |
| Shares Outstanding | 78 520 000 |
| Percentage of Shares Shorted | 5.43% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 106 full-time employees. The company went IPO on 2021-07-30. The firm is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The company is advancing a pipeline of disease-modifying therapies developed using its product platforms and capabilities to target defined sub-populations of patients with rare or other prevalent forms of heart disease. The firm is advancing product candidates from three diverse product platforms, such as gene therapy, cellular regeneration, and precision medicine. The company is also advancing a diverse pipeline that includes both gene therapies and small molecules. The Company’s capabilities include disease models, capsid engineering, promoters and regulatory elements, drug delivery and manufacturing.
You don't have any saved screeners yet
